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Abstract
Background: Various agents and techniques have been introduced to limit intra-operative blood loss from skin
lesions. No uniformity regarding the type of haemostasis exists and this is generally based on the surgeon’s
preference. To study the effectiveness of haemostatic agents, standardized wounds like donor site wounds after
split skin grafting (SSG) appear particularly suitable. Thus, we performed a systematic review to assess the
effectiveness of haemostatic agents in donor site wounds.
Methods: We searched all randomized clinical trials (RCTs) on haemostasis after SSG in Medline, Embase and the
Cochrane Library until January 2011. Two reviewers independently assessed trial relevance and quality and
performed data analysis. Primary endpoint was effectiveness regarding haemostasis. Secondary endpoints were
wound healing, adverse effects, and costs.
Results: Nine relevant RCTs with a fair methodological quality were found, comparing epinephrine, thrombin, fibrin
sealant, alginate dressings, saline, and mineral oil. Epinephrine achieved haemostasis significantly faster than
thrombin (difference up to 2.5 minutes), saline or mineral oil (up to 6.5 minutes). Fibrin sealant also resulted in an
up to 1 minute quicker haemostasis than thrombin and up to 3 minutes quicker than placebo, but was not
directly challenged against epinephrine. Adverse effects appeared negligible. Due to lack of clinical homogeneity,
meta-analysis was impossible.
Conclusion: According to best available evidence, epinephrine and fibrin sealant appear superior to achieve
haemostasis when substantial topical blood loss is anticipated, particularly in case of (larger) SSGs and burn
debridement.
Background
Limitation of intra-operative blood loss from skin lesions
is an important aspect of surgical procedures [1]. Effec-
tive and fast haemostasis results in less time spent in the
operating room, a more favourable outcome for the
patient being under anaesthesia, and an uneventful
wound healing process. When substantial blood loss is
encountered, haemostasis can play a crucial role in avoid-
ing major haemostatic disturbances [2].
In order to minimize blood loss, for example in
patients with large burns after excision of these burns,
several treatment options have been introduced such as
intravenous vasoconstrictive agents, tourniquets, topical
haemostatic agents or subcutaneous agents (i.e. the
tumescent technique, frequently used for varicectomy or
suction lipectomy) [3-7].
Unfortunately, haemostasis is an understudied subject
in the surgical field, and current practice is based on
beliefs and habits rather than on evidence [8]. In other
words, a so-called ‘gold standard’ regarding topical hae-
mostasis does not exist. Recently published reviews all
conclude that multiple factors determine the agent of
choice, including familiarity with the products, patient
characteristics and costs [2,8]. Hence, the best choice
for achieving haemostasis remains unclear.
For this reason, we decided to investigate the available
high-level evidence from the medical literature on all
topically applied haemostatic agents. To best appreciate
their effects without interference from different types of
wound, we chose a quite standardized wound type, i.e.
donor sites after split-skin grafting (SSG) as the site of
intervention. SSG is a widely used procedure by different
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due to various causes, such as (burning) trauma, chronic
ulceration, or as part of plastic surgical procedures [3,9].
Although most donor sites are small and do not necessa-
rily require haemostatic treatment, they are well suitable
for the examination of superficial bleeding and the
response to haemostatic agents applied.
Although several comparative studies on haemostasis
of donor sites have been reported, very few showed sig-
nificant outcomes [4-7]. This was mainly due to small
populations, incomparable treatments, and other forms
of bias. Hence, the primary aim of this study was to
summarize all available strong evidence for the best way
(s) for haemostasis in patients with donor sites of SSGs.
Methods
The conduct and reporting of this systematic review
have been performed according to the PRISMA state-
ment [10].
Search Strategy
We searched MEDLINE, Cochrane Database, and
EMBASE up to January 2011 together with our clinical
librarian. Keywords used were: (skin transplant* OR (skin
transplantation[MeSH] OR (skin graft* OR skin graft
[MeSH]))) AND (((hemostasis[MeSH]) OR (hemostatic
[MeSH]) OR (haemostatic[MeSH])) OR (hemosta*)). No
limits as to language or publication status were applied.
Two reviewers (MG&AG) independently scanned the
retrieved abstracts for relevant studies. To be included,
articles had to show: (1) the way of achieving haemosta-
sis of the donor site during or after split skin harvest,
and (2) a randomised clinical trial (RCT). Exclusion cri-
teria were: clinical comparative studies, case series, case
reports, letters, or abstracts. In case of disagreement
between the two reviewers, a third reviewer (DU) was
involved.
Haemostatic Agents, Outcome Measures, and Data
Analysis
All agents or techniques used to reduce blood loss from
donor sites were included.
Results of each trial were examined with regard to four
outcome measures: blood loss (reported using different
parameters, e.g. amount of blood (products) in gauzes,
swabs or filters, time to haemostasis, use of electrocau-
tery, need for blood transfusions), donor site wound heal-
ing, adverse effects, and costs.
Data were entered into Revman (version 5.0.23,
Cochrane Collaboration) and 95% confidence intervals
(CI) were calculated for every comparison. For continu-
ous outcomes, mean differences (MD) were calculated.
For dichotomous outcomes, risk ratios (RR) and num-
bers needed to treat (NNT) were used.
Assessment of Methodological Quality
Methodological quality of the RCTs was assessed using
‘T h eC o c h r a n eC o l l a b o r a t i o n ’s Tool for Assessing Risk
of Bias’ [11]. Again, this assessment was made by two
reviewers independently (MG&AG).
Results
Description of trials
We found 647 potentially relevant titles. After screening
of titles or abstracts 17 articles matched our inclusion
criteria. Full texts were screened and eventually, 9 rele-
vant articles were included. Study inclusion and reasons
for exclusion are summarised in Figure 1. Trial sizes ran-
ged from 5 to 56 patients totalling 376 donor sites in 340
(mainly burn) patients. In five trials donor sites were
divided in two equivalently sized halves, while patients
functioned as their own controls [12-16]. Three trials
[17-19] compared entire donor sites, while one trial [20]
only included patients with two similar donor sites (i.e.
opposite thighs). In one trial, the haemostatic effect of
alginate dressings was investigated. This possible effect
has been ascribed to their calcium content, being an
important element in the coagulation cascade [21]. Trial
characteristics are summarised in table 1. Due to a large
variability of outcome measurements and comparisons,
no meta-analyses could be performed.
Risk of bias in included trials
Methodological quality was generally fair and is sum-
marised in figure 2. Study groups also appeared compar-
able at baseline. None of the included trials used a
power analysis to calculate the minimal sample size
required to achieve statistical significance for the esti-
mated treatment effect.
Effects of interventions (see table 2)
Comparison 1. Epinephrine vs. thrombin (3 trials)
1.1 Haemostatic Effect
1.1.1 Blood loss
Brezel et al. reported less bleeding was visually stated at
epinephrine treated sites in significantly more patients
(29 out of 32), than at thrombin treated sides (0 out of
32) (RR 59.00; 95%CI 3.76 to 925.91; NNT = 2). Size of
grafted areas was not reported[13].
Carucci et al. reported that the amount of blood
absorbed was significantly less from donor sites treated
with phenylephrine than with thrombin (p < 0.05) [14].
We had no access to original data and therefore could not
check this result. All assessed donor sites were 200 cm
2.
1.1.2 Time to haemostasis
Netscher et al. compared two epinephrine-containing
agents to thrombin [19]. Both epinephrine/K-Y jelly
(MD -2.30; 95%CI -3.83 to -0.77 minutes) and
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utes) resulted in significantly quicker haemostasis than
treatment with thrombin. Size of grafted areas ranged
from 15 to 891 cm
2.
1.2 Adverse effects
All three trials described that adverse or systemic effects
due to treatment with epinephrine or thrombin did not
occur.
1.3 Costs
Brezel et al. reported that use of epinephrine compared
to thrombin would save the hospital US$9.85, and the
patient US$19.50 per grafting procedure[13].
Carucci et al. reported costs for haemostatic treat-
ment per patient was US$3 for treatment with pheny-
lephrine, and US$92 for treatment with thrombin [14].
Both studies reported on direct costs without statistical
analysis.
Table 1 Characteristics of included studies
Trial Patients Intervention Comparison Outcomes
Barret JP,
1999
42 pediatric burn patients
(21 vs. 21)
Epinephrine 1:10.000 (and
thrombin 1:300.000)
(topical)
Saline (and thrombin) Blood loss in ml and ml/cm
2, Ht, Hb up to 8
hours post-operatively, blood transfusions
Brezel BS,
1987
32 burn patients (32 vs. 32) Epinephrine 1:200.000
(topical)
Thrombin Blood loss visually estimated from photographs 5
minutes post-operatively
Gacto P,
2008
56 burn patients (25 vs. 31) Epinephrine-lidocaine
Subcutaneous 1:500.000
Saline Overall blood loss visually estimated, use of
electrocautery, days hydrocolloid maintained
Netscher
DT, 1996
52 patients (12 vs. 8 vs. 12 vs.
7 vs. 13)
Epinephrine/K-Y jelly
1:50.000 (topical)
Epinephrine spray,
thrombin, K-Y jelly,
mineral oil.
Time to haemostasis (minutes)
Carucci DJ,
1984
24 patients (6 vs. 6 vs. 12) Phenylephrine 1:20.000
(topical)
Thrombin Blood loss measured by Hb in paper disks
Greenhalgh
DG, 1999
34 burn patients (<15%
TBSA) (34 vs. 34)
Fibrin sealant (duoflo
Y-shaped adapter)
Placebo Blood loss visually estimated and measured by Hb
in sponges, donor site healing viewed on
photographs
Nervi C,
2001
61 burn patients (donor site
2-8% TBSA) (61 vs. 61)
Fibrin sealant (duoflo
Y-shaped adapter)
Placebo Time to haemostasis
Drake DB,
2003
34 patients with SSG areas
5-15 cm (34 vs. 34)
Fibrin sealant (Vivostat) Thrombin Time to haemostasis (seconds)
Steenfos
HH, 1998
5 patients (7 donor sites)
(7 vs. 7)
Alginate dressing Fine mesh gauze Blood loss measured by iron content of dressings
Figure 1 Literature search and article selection. RCTs; randomised clinical trials.
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stated that thrombin spray was by far most expensive [19].
Adequate sequence generation?
Allocation concealment?
Free of selective reporting?
Free of other bias?
Financial support?
Blinding? (Care provider)
Blinding? (Participant)
Blinding? (Outcome assessor)
Incomplete outcome data addressed? (drop-out rate acceptable?)
Incomplete outcome data assessed? (Intention to treat?)
0% 25% 50% 75% 100%
Yes (low risk of bias) Unclear No (high risk of bias)
Figure 2 Risk of bias table showing the methodological quality assessment of the 9 included RCTs.
Table 2 Effects of interventions sorted by comparison
Comparison Trial Haemostatic
effect
Healing Adverse
effects
Costs
1. Epinephrine vs. thrombin Brezel et al. 1987 + NS NS direct costs in favour of
epinephrine
Carucci et al. 1984 + no data NS probably favouring epinephrine
Netscher et al.
1996
+ no data NS direct costs in favour of
epinephrine*
2. Epinephrine vs. control Carucci et al. 1984 + no data NS probably favouring control*
Gacto et al. 2008 + favouring
epinephrine
NS no data
Netscher et al.
1996
+ no data NS probably favouring control*
Barret et al. 1999 NS NS NS no data
3. Fibrin sealant vs. control Nervi et al. 2001 + no data no data no data
Greenhalgh et al.
1999
+/NS/NS** NS NS no data
4. Fibrin sealant vs. thrombin Drake et al. 2003 + NS NS no data
5. Thrombin vs. control Carucci et al. 1984 + no data NS probably favouring control*
Netscher et al.
1996
+ no data NS probably favouring control*
6. Alginate dressing vs. fine mesh
gauze
Steenfos et al. 1998 + NS NS no data
+ = significantly in favour of the former agent;
- = significantly in favour of the latter agent;
NS = not significant.
* Only direct costs per product or per patient were given, so no conclusion on overall costs per treatment could be conducted.
** Blood loss was estimated in three different ways.
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mineral oil/K-Y jelly; 4 trials)
2.1 Haemostatic Effect
2.1.1 Blood loss
Gacto et al. found a significant difference in blood loss,
when comparing visually estimated blood loss from donor
site areas [18]. Blood loss was estimated as “less than nor-
mal” in 29 (out of 31) cases treated with epinephrine, com-
pared to 9 (out of 25) cases treated with saline (RR: 2.60;
95%CI 1.53 to 4.42; NNT = 2). Also electrocautery was
significantly less used after application of epinephrine; 2
versus 16 patients (RR 0.10; 95%CI 0.03 to 0.40). Addition-
ally, hydrocolloid dressings remained in situ significantly
more days after treatment with epinephrine (MD 3.55;
95%CI 2.63 to 4.47). The mean donor site size was 3.9%
(SD 2%) of total body surface (TBSA).
Carucci et al. reported that amount of blood absorbed
in donor sites treated with phenylephrine was signifi-
cantly less than in those treated with saline (p < 0.05)
[14]. The size of all assessed donor sites was 200 cm
2.
Barret et al. reported no significant difference in blood
loss (MD -228.00; 95%CI -908.51 to 452.51 ml). Even
when corrected for grafted area (ml/cm
2) the difference
remained insignificant (MD -0.02; 95%CI -0.11 to 0.05)
[15]. No significance in the number of blood transfu-
sions (RR 0.75; 95%CI 0.19 to 2.95) was found. Sizes of
grafted areas ranged from 0 to 5000 cm
2.
2.1.2 Time to haemostasis
Netscher et al. compared epinephrine spray and epi-
nephrine/K-Y jelly mixture to mineral oil and K-Y jelly
alone [19]. With both epinephrine-containing agents,
haemostasis was achieved significantly faster than with
control agents. Epinephrine spray was faster than mineral
oil (MD -6.25; 95%CI -7.88 to -4.62 minutes) and K-Y
jelly (MD -5.00; 95%CI -7.38 to -2.62 minutes). Epinephr-
ine/K-Y jelly mixture was also faster than mineral oil
(MD -6.36; 95%CI -7.63 to -5.09 minutes) and K-Y jelly
alone (MD -5.11; 95%CI -7.27 to -2.95 minutes). The size
of grafted area ranged from 15 to 891 cm
2.
2.2 Healing
Gacto et al. reported the proportion of re-epithelialised
skin after 1 week was 98.5% in the group treated with epi-
nephrine, and 71% in the group treated with saline [18].
Netscher et al. did not report any (negative) effect on
wound healing [19]. Barret et al. reported comparable
wound healing of donor sites in both study groups [17].
2.3 Adverse effects
No differences in complications, side effects, or adverse
events were reported in any trial.
Comparison 3. Fibrin sealant vs. control (2 trials)
3.1 Haemostatic Effect
3.1.1 Blood loss
Greenhalgh et al. reported that estimated blood loss by
registering blood-soaked swabs did not result in a signifi-
cant difference (MD -5.00; 95%CI -128.37 to 118.37 ml)
between the fibrin sealant group 245 ± 283 ml) and the
control group (250 ± 280 ml) [20]. Additionally, no signifi-
cant differences were found in haemoglobin concentra-
tions measured in laparotomy sponges (n = 41) that were
placed on donor sites during 1 minute postoperatively
(MD -0.03; 95%CI -0.29 to 0.23 absorbance value), and
during following 5 minutes postoperatively (MD -0.12;
95%CI -0.47 to 0.23 absorbance value). Absorbance values
were determined at 540 nm from a solution of eluted hae-
moglobin into 1 litre 0.007 M ammonium-hydroxide.
Mean size of grafted area was 5.5% TBSA (ranging from 1
to 14.8%).
3.1.2 Time to haemostasis
Nervi et al. reported less mean time (seconds) to haemos-
tasis after treatment with fibrin sealant (193 ± 131 s),
compared to no treatment (392 ± 153 s) (MD -199; 95%
CI -249.55 to -148.45 s) [15]. Mean size of grafted areas
was 3.4% TBSA (SD 1.2%).
3.2 Healing
Greenhalgh et al. reported no differences in rates of
wound healing between both groups [20]. They also
compared eventual cosmetic appearance. No significant
differences were noted; 94.1% of the fibrin sealant group
was ranked as good/excellent compared to 89.3% of the
control group.
3.3 Adverse effects
Greenhalgh et al. reported one adverse event that was
due to use of fibrin sealant (graft loss by excessive
application of fibrin sealant) [20]. However, this
referred to an adverse effect located on the recipient
site. When fibrin sealant is exclusively used for hae-
mostasis, this adverse effect does not appear of great
importance.
Comparison 4. Fibrin sealant vs. thrombin (1 trial)
4.1 Haemostatic Effect
4.1. Time to haemostasis
Drake et al. recorded significantly less time (seconds) to
haemostasis in areas treated with fibrin sealant (mean 68,
range 5 to 398 s), than with thrombin (mean 135, range
22 to 601 s) (MD -67.00; 95%CI -126.84 to -7.16 s). Sizes
of grafted areas were not reported [12].
4.2 Adverse effects
No adverse effects were considered related to fibrin sea-
lant use [12].
Groenewold et al. BMC Surgery 2011, 11:15
http://www.biomedcentral.com/1471-2482/11/15
Page 5 of 8Comparison 5. Thrombin vs. control (saline/
mineral oil/K-Y jelly; 2 trials)
5.1 Haemostatic Effect
5.1.1 Blood loss
Carucci et al. reported blood absorbed from donor sites
treated with thrombin was significantly less than from
sites treated with saline (p < 0.05) [14]. The size of all
grafted areas was 200 cm
2.
5.1.2 Time to haemostasis
Netscher et al. reported that haemostasis is achieved sig-
nificantly faster (in minutes) after treatment with throm-
bin, than with mineral oil (MD -4.06; 95%CI -5.81 to
-2.31), or K-Y jelly (MD -2.81; 95%CI -5.28 to -0.34).
Size of grafted area ranged from 15 to 891 cm
2 [19].
5.2 Healing
Netscher et al. reported uniform wound healing among
study groups measured by observation, but no data were
reported [19].
5.4 Costs
Carucci et al. reported costs for haemostatic treatment
with thrombin were US$92 per patient, but those for
saline were not mentioned [14].
Netscher et al. only stated that thrombin spray was by
far the most expensive product [19]. They did not report
costs per patient or per treatment.
Comparison 6. Alginate dressing vs. fine mesh
gauze (1 trial)
6.1 Haemostatic Effect
6.1.1 Blood loss
Steenfos et al. reported a significantly higher amount of
blood absorption 10 minutes postoperatively by alginate
dressings (μgF e / c m
2 wound area) (mean 1110, SD 262),
compared to mesh gauze dressings (mean 774, SD 314)
(MD -336; 95%CI -638.95, -33.05) [16]. The average size
of donor sites was 105 cm
2.
6.2 Healing
No significant differences were reported in number of
donor sites completely epithelialised at day 6 between
sites treated with alginate (9 out of 22) and mesh gauze
(7 out of 22) (RR 1.29; 95%CI 0.58 to 2.84) [16].
6.3 Adverse effects
They also reported no complications with either treat-
ment [16].
Discussion
This systematic review shows evidence for the haemostatic
effect of epinephrine, fibrin sealant, thrombin, and algi-
nates on donor sites after split-skin grafting. In particular,
epinephrine and fibrin sealant seem to be superior over
other haemostatic products or placebo to reduce blood
loss. These agents can shorten time to haemostasis with
about 3 to 6 minutes. However, costs of the use of these
agents are poorly investigated, as well as their effect on
wound healing. This weakens the possibility to decide for
a certain haemostatic agent based on the evidence pre-
sently available.
Unfortunately, no trial directly compared epinephrine to
fibrin sealant. Hence, it remains unclear which of the two
agents is preferable for haemostasis. Epinephrine and
fibrin sealant appear superior to thrombin, which per se
has better haemostatic properties than mineral oil, K-Y
jelly, or saline. Effect sizes were mainly described in terms
of minutes to haemostasis rather than an accurate appre-
ciation of the amount of blood loss. This time gain seems
subordinate to the actual blood loss. Anyhow, use of these
agents appears helpful when large skin transplants are
needed or considerable blood loss is anticipated, for exam-
ple in burn wound resections.
Only four out of nine trials presented results on cos-
metic appearance or wound healing, which may have been
hampered by prolonged blood or fluid loss from the donor
site. No trial showed any adverse effects of local haemo-
statics, in particular no systemic adrenergic side effects
due to epinephrine, as described previously by Hughes et
al. [8]. Considering costs of treatment, epinephrine seems
less expensive than thrombin and fibrin sealant, but evi-
dence and uniformity on this matter is lacking.
Recently, newly developed haemostatic agents, such as
platelet gel, CoSeal
®,B i o G l u e
® or Ostene
® were intro-
duced [22,23], but were not included in our systematic
review, because no randomized controlled trials were per-
formed yet comparing these agents in skin lesions.
T h ee v i d e n c eo b t a i n e dh a ss o me limitations. First of
all, some trials used rather vague and subjective out-
come measurements, while explicit recording and
reporting of adverse effects was rare. Two trials
assessed blood loss by visually estimating the amount
of blood, which is imprecise and sensitive to bias.
Although results were significant, clinical relevance
remains questionable. Second, blinding of care provi-
ders (surgeons and nurses, who usually also assess the
outcome) was difficult to accomplish because of the
differing application of haemostatic agents (different
gauzes, injections, applicators). In most trials patients
were probably blinded, because they are unconscious
during the SSG procedure, and are likely not to be
informed about which haemostatic treatment they
received. However, three trials specifically reported
blinding of the outcome assessor(s). This is the best
option to reduce the risk of bias if blinding of care-
givers and patients is impossible.
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neck et al. [22] discussed the mechanism of action, (dis)
advantages, and recommendations for use of multiple
(new) topical haemostatic agents. Unfortunately, part of
their evidence was based on case series and case reports,
having a high risk of bias. The authors recommended sev-
eral agents for different procedures. They conclude that
the ideal haemostatic agent does not exist and the agent of
choice depends on several aspects such as type of proce-
dure, mechanism of action, and patient characteristics.
According to the present review of efficacy, adverse effects,
and healing properties, epinephrine and fibrin sealant
come close to being ideal. Furthermore, epinephrine is
relatively inexpensive. In another review, Samudrala et al.
[23] describe principles of haemostasis and mechanisms of
action of several agents. They conclude, based also on
non-comparative studies, that use of haemostatic agents in
general contributes to faster patient recovery time, avoids
adverse events, and reduces overall procedure time. This
supports the evidence found in our review, although effect
sizes differ greatly among different agents. In addition,
familiarity with these products and their preparation is a
prerequisite for optimal use and to improve patient
outcomes.
In order to determine the single most effective agent for
haemostasis, further investigation is required. For this pur-
pose, blood loss should be reported in an objective and
precise manner. Moshaver et al. [24] measured blood loss
during endoscopic sinus surgery using a ‘standardized
scale’: evaluating blood loss by the need of electrocautery.
Even though such definitions are detailed, its applicability
still remains questionable. The best method of assessing
wound healing is also unclear. The most accurate and
objective method used by Steenfos et al. [16] consisted of
assessing punch biopsies by a pathologist masked for the
treatment given. Although this method leaves little subjec-
tivity, it informed only on healing speeds, not on quality.
Conclusions
Haemostatic agents are particularly useful for patients
requiring larger split skin graft harvests, burn wound deb-
ridement, or for other reasons why minimisation of (topi-
cal) blood loss is desired. According to best available
evidence as summarised in this review, epinephrine and
fibrin sealant appear superior agents for achieving quick
and effective haemostasis. Both agents reduce the amount
and the time of bleeding, while they do not seem to impair
wound healing or lead to other adverse events. It remains
unclear which of these two agents is to be preferred as to
healing quality, safety, and costs. A well-performed rando-
mised clinical trial comparing at least epinephrine and
fibrin sealant is desirable to produce high-quality and
clinically relevant results. For this purpose we recommend
the use of clear outcome measures (including side effects,
wound healing, and safety), blinded outcome assessors,
and an economic evaluation.
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